Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes (NCT07485062) | Clinical Trial Compass
Not Yet RecruitingPhase 4
Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes
Canada164 participantsStarted 2026-05-01
Plain-language summary
Type 2 diabetes and low levels of physical activity are associated with an increased risk of cognitive decline in older adults. Improving blood sugar control and engaging in regular exercise may help support brain health and physical function in this population.
The MOTIVATE study is a randomized clinical trial designed to examine the effects of supervised exercise and diabetes treatment with semaglutide, alone or in combination, on cognitive function, physical health, and brain-related outcomes in older adults with Type 2 diabetes. Participants will be assigned to one of four study groups involving exercise training, control exercise, semaglutide treatment, or standard diabetes care.
Participants will complete supervised exercise sessions three times per week for 32 weeks, with some participants also receiving weekly semaglutide injections for 16 weeks. Assessments will include cognitive testing, physical and functional measures, blood-based metabolic markers, and brain imaging. This study aims to improve understanding of how exercise and diabetes treatments may support brain health in older adults with Type 2 diabetes.
Who can participate
Age range65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
✓. Community-dwelling
✓. Male or female
✓. Age ≥ 65 at the time of signing informed consent
✓. Glycated hemoglobin levels of ≥7% (i.e., A1c levels high enough to see intervention-related changes and increase eligibility for recruitment, but can exercise safely)
✓. Eligible for the Ontario Drug Benefit (inadequate glycemic control and on max tolerated dose of metformin or metformin contraindicated or inappropriate)
✓. Score \>24/30 on the Mini-Mental State Exam (MMSE)
✓. Score \>6/8 on the Lawton Instrumental Activities of Daily Living Scale (IADL)
Exclusion criteria
✕. Have a medical condition for which semaglutide or exercise is contraindicated
✕. Use of a GLP-1 receptor agonist in the past 6 months (i.e., offers removal of Semaglutide from the system as it has a half-life of around 1 week; thus, 8-10 weeks are required for a washout.